{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:55:59Z","timestamp":1793318159615,"version":"4.5.0"},"reference-count":80,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:p>Adrenocortical carcinoma (ACC) accounts for a minority of all malignant tumors in adults. Surgery remains the most important therapeutic option for non-metastatic ACC. Whether a subset of patients with small ACC may benefit from minimally invasive surgery remains a debated issue, but we believe that surgeon\u2019s expertise is more important than surgical technique to determine outcome. However, even a state-of-the-art surgery cannot prevent disease recurrence that is determined mainly by specific tumor characteristics. We consider that the concomitant presence of the following features characterizes a cohort of patients at low risk of recurrence, (i) R0 resection (microscopically free margin), (ii) localized disease (stage I-II ACC), and (iii) low-grade tumor (ki-67 &lt;10%). After the ADIUVO study, we do not recommend adjuvant mitotane as a routine measure for such patients, who can be managed with active surveillance thus sparing a toxic treatment. Patients at average risk of recurrence should be treated with adjuvant mitotane. For patients at very high risk of recurrence, defined as the presence of at least one of the following: Ki67 &gt;30%, large venous tumor thrombus, R1 resection or stage IV ACC, we increasingly recommend to combine mitotane with four cycles of platinum-based chemotherapy. However, patients at moderate-to-high risk of recurrence should be ideally enrolled in the ongoing ADIUVO2 trial. We do not use adjuvant radiotherapy of the tumor bed frequently at our institutions, and we select patients with incomplete resection, either microscopically or macroscopically, for this treatment. In the long-term, prospective multicenter trials are required to improve patient care.<\/jats:p>","DOI":"10.1530\/eje-22-0260","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T13:09:00Z","timestamp":1655125740000},"page":"R27-R40","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-7","source":"Crossref","is-referenced-by-count":28,"title":["ENDOCRINE TUMOURS: Our experience with the management of patients with non-metastatic adrenocortical carcinoma"],"prefix":"10.1093","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4171-2851","authenticated-orcid":true,"given":"Massimo","family":"Terzolo","sequence":"first","affiliation":[{"name":"Internal Medicine, Department of Clinical and Biological Sciences, S. Luigi Hospital, Orbassano, University of Turin, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6170-6398","authenticated-orcid":true,"given":"Martin","family":"Fassnacht","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes, Department of Internal Medicine, University Hospital, University of Wu\u0308rzburg, Wu\u0308rzburg, Germany"},{"name":"Comprehensive Cancer Center Mainfranken, University of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"bib1","series-title":"European Journal of Cancer","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1016\/j.ejca.2013.02.034","article-title":"Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993","volume":"49","author":"Kerkhofs","year":"2013","unstructured":"Kerkhofs TMVerhoeven RHVan der Zwan JMDieleman JKerstens MNLinks TPVan de Poll-Franse LVHaak HR. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. European Journal of Cancer2013492579\u20132586. (https:\/\/doi.org\/10.1016\/j.ejca.2013.02.034)10.1016\/j.ejca.2013.02.034"},{"key":"bib2","series-title":"World Journal of Surgery","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s00268-005-0329-x","article-title":"Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?","volume":"30","author":"Kebebew","year":"2006","unstructured":"Kebebew EReiff EDuh QYClark OHMcMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?World Journal of Surgery200630872\u2013878. (https:\/\/doi.org\/10.1007\/s00268-005-0329-x)10.1007\/s00268-005-0329-x"},{"key":"bib3","series-title":"European Journal of Endocrinology","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","unstructured":"Fassnacht MDekkers OMElse TBaudin EBerruti Ade Krijger RRHaak HRMihai RAssie GTerzolo M. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. European Journal of Endocrinology2018179G1\u2013G46. (https:\/\/doi.org\/10.1530\/EJE-18-0608)10.1530\/EJE-18-0608"},{"key":"bib4","series-title":"Annals of Oncology","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","unstructured":"Fassnacht MAssie GBaudin EEisenhofer Gde la Fouchardiere CHaak HRde Krijger RPorpiglia FTerzolo MBerruti AAdrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology2020311476\u20131490. (https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2099)10.1016\/j.annonc.2020.08.2099"},{"key":"bib5","series-title":"Best Practice and Research: Clinical Endocrinology and Metabolism","article-title":"New perspectives for mitotane treatment of adrenocortical carcinoma","volume":"34","author":"Puglisi","year":"2020","unstructured":"Puglisi SCalabrese ABasile VPia AReimondo GPerotti PTerzolo M. New perspectives for mitotane treatment of adrenocortical carcinoma. Best Practice and Research: Clinical Endocrinology and Metabolism202034 101415. (https:\/\/doi.org\/10.1016\/j.beem.2020.101415)"},{"key":"bib6","series-title":"Nature Reviews: Endocrinology","first-page":"323","article-title":"Adrenocortical carcinoma: a clinician\u2019s update","volume":"7","author":"Fassnacht","year":"2011","unstructured":"Fassnacht MLibe RKroiss MAllolio B. Adrenocortical carcinoma: a clinician\u2019s update. Nature Reviews: Endocrinology20117323\u2013335. (https:\/\/doi.org\/10.1038\/nrendo.2010.235)"},{"key":"bib7","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1210\/jc.2012-2559","article-title":"The role of surgery in the management of recurrent adrenocortical carcinoma","volume":"98","author":"Erdogan","year":"2013","unstructured":"Erdogan IDeutschbein TJurowich CKroiss MRonchi CQuinkler MWaldmann JWillenberg HSBeuschlein FFottner CThe role of surgery in the management of recurrent adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism201398181\u2013191. (https:\/\/doi.org\/10.1210\/jc.2012-2559)10.1210\/jc.2012-2559"},{"key":"bib8","series-title":"European Journal of Endocrinology","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1530\/EJE-18-0923","article-title":"Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence","volume":"180","author":"Calabrese","year":"2019","unstructured":"Calabrese ABasile VPuglisi SPerotti PPia ASaba LBerchialla PPorpiglia FVeltri AVolante MAdjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. European Journal of Endocrinology2019180387\u2013396. (https:\/\/doi.org\/10.1530\/EJE-18-0923)10.1530\/EJE-18-0923"},{"key":"bib9","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.1210\/jc.2008-0579","article-title":"Adjuvant mitotane for adrenocortical cancer \u2013 a recurring controversy","volume":"93","author":"Huang","year":"2008","unstructured":"Huang HFojo T. Adjuvant mitotane for adrenocortical cancer \u2013 a recurring controversy. Journal of Clinical Endocrinology and Metabolism2008933730\u20133732. (https:\/\/doi.org\/10.1210\/jc.2008-0579)10.1210\/jc.2008-0579"},{"key":"bib10","series-title":"Endocrinology and Metabolism Clinics of North America","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ecl.2018.02.003","article-title":"Adrenocortical carcinoma with hypercortisolism","volume":"47","author":"Puglisi","year":"2018","unstructured":"Puglisi SPerotti PPia AReimondo GTerzolo M. Adrenocortical carcinoma with hypercortisolism. Endocrinology and Metabolism Clinics of North America201847395\u2013407. (https:\/\/doi.org\/10.1016\/j.ecl.2018.02.003)10.1016\/j.ecl.2018.02.003"},{"key":"bib11","series-title":"Current Opinion in Endocrinology, Diabetes, and Obesity","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/MED.0000000000000626","article-title":"Approach to patients with European Network for the study of adrenal tumor stages I and II adrenocortical carcinomas","volume":"28","author":"Kastelan","year":"2021","unstructured":"Kastelan DMuzurovic EDusek T. Approach to patients with European Network for the study of adrenal tumor stages I and II adrenocortical carcinomas. Current Opinion in Endocrinology, Diabetes, and Obesity202128265\u2013270. (https:\/\/doi.org\/10.1097\/MED.0000000000000626)10.1097\/MED.0000000000000626"},{"key":"bib12","series-title":"European Journal of Endocrinology","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-16-0467","article-title":"Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the study of adrenal tumors","volume":"175","author":"Fassnacht","year":"2016","unstructured":"Fassnacht MArlt WBancos IDralle HNewell-Price JSahdev ATabarin ATerzolo MTsagarakis SDekkers OM. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the study of adrenal tumors. European Journal of Endocrinology2016175G1\u2013G34. (https:\/\/doi.org\/10.1530\/EJE-16-0467)10.1530\/EJE-16-0467"},{"key":"bib13","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/cncr.24030","article-title":"Limited prognostic value of the 2004 International Union against cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM Classification","volume":"115","author":"Fassnacht","year":"2009","unstructured":"Fassnacht MJohanssen SQuinkler MBucsky PWillenberg HSBeuschlein FTerzolo MMueller HHHahner SAllolio BLimited prognostic value of the 2004 International Union against cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM Classification. Cancer2009115243\u2013250. (https:\/\/doi.org\/10.1002\/cncr.24030)10.1002\/cncr.24030"},{"key":"bib14","series-title":"New England Journal of Medicine","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","author":"Terzolo","year":"2007","unstructured":"Terzolo MAngeli AFassnacht MDaffara FTauchmanova LConton PARossetto RBuci LSperone PGrossrubatscher EAdjuvant mitotane treatment for adrenocortical carcinoma. New England Journal of Medicine20073562372\u20132380. (https:\/\/doi.org\/10.1056\/NEJMoa063360)10.1056\/NEJMoa063360"},{"key":"bib15","series-title":"Cancer","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1002\/cncr.23886","article-title":"Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors","volume":"113","author":"Bilimoria","year":"2008","unstructured":"Bilimoria KYShen WTElaraj DBentrem DJWinchester DJKebebew ESturgeon C. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer20081133130\u20133136. (https:\/\/doi.org\/10.1002\/cncr.23886)10.1002\/cncr.23886"},{"key":"bib16","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1210\/jc.2014-3182","article-title":"Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection","volume":"100","author":"Beuschlein","year":"2015","unstructured":"Beuschlein FWeigel JSaeger WKroiss MWild VDaffara FLib\u00e9 RArdito AAl Ghuzlan AQuinkler MMajor prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. Journal of Clinical Endocrinology and Metabolism2015100841\u2013849. (https:\/\/doi.org\/10.1210\/jc.2014-3182)10.1210\/jc.2014-3182"},{"key":"bib17","series-title":"Human Pathology","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.humpath.2020.10.001","article-title":"Data set for reporting of carcinoma of the adrenal cortex: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting","volume":"110","author":"Giordano","year":"2021","unstructured":"Giordano TJBerney Dde Krijger RRErickson LFassnacht MMete OPapathomas TPapotti MSasano HThompson LDRData set for reporting of carcinoma of the adrenal cortex: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Human Pathology202111050\u201361. (https:\/\/doi.org\/10.1016\/j.humpath.2020.10.001)10.1016\/j.humpath.2020.10.001"},{"key":"bib18","series-title":"American Journal of Surgical Pathology","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/PAS.0000000000000574","article-title":"An international Ki67 reproducibility study in adrenal cortical carcinoma","volume":"40","author":"Papathomas","year":"2016","unstructured":"Papathomas TGPucci EGiordano TJLu HDuregon EVolante MPapotti MLloyd RVTischler ASvan Nederveen FHAn international Ki67 reproducibility study in adrenal cortical carcinoma. American Journal of Surgical Pathology201640569\u2013576. (https:\/\/doi.org\/10.1097\/PAS.0000000000000574)10.1097\/PAS.0000000000000574"},{"key":"bib19","series-title":"European Urology","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.eururo.2013.11.006","article-title":"Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer","volume":"65","author":"Berruti","year":"2014","unstructured":"Berruti AFassnacht MHaak HElse TBaudin ESperone PKroiss MKerkhofs TWilliams ARArdito APrognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. European Urology201465832\u2013838. (https:\/\/doi.org\/10.1016\/j.eururo.2013.11.006)10.1016\/j.eururo.2013.11.006"},{"key":"bib20","series-title":"American Journal of Surgery","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.amjsurg.2015.09.020","article-title":"Outcomes after resection of cortisol-secreting adrenocortical carcinoma","volume":"211","author":"Margonis","year":"2016","unstructured":"Margonis GAKim YTran TBPostlewait LMMaithel SKWang TSGlenn JAHatzaras IShenoy RPhay JEOutcomes after resection of cortisol-secreting adrenocortical carcinoma. American Journal of Surgery20162111106\u20131113. (https:\/\/doi.org\/10.1016\/j.amjsurg.2015.09.020)10.1016\/j.amjsurg.2015.09.020"},{"key":"bib21","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1210\/jc.2005-2730","article-title":"Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients","volume":"91","author":"Abiven","year":"2006","unstructured":"Abiven GCoste JGroussin LAnract PTissier FLegmann PDousset BBertagna XBertherat J. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. Journal of Clinical Endocrinology and Metabolism2006912650\u20132655. (https:\/\/doi.org\/10.1210\/jc.2005-2730)10.1210\/jc.2005-2730"},{"key":"bib22","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"3566","DOI":"10.1210\/jc.2018-00918","article-title":"Predictors of survival in adrenocortical carcinoma: an analysis from the National Cancer Database","volume":"103","author":"Tella","year":"2018","unstructured":"Tella SHKommalapati AYaturu SKebebew E. Predictors of survival in adrenocortical carcinoma: an analysis from the National Cancer Database. Journal of Clinical Endocrinology and Metabolism20181033566\u20133573. (https:\/\/doi.org\/10.1210\/jc.2018-00918)10.1210\/jc.2018-00918"},{"key":"bib23","series-title":"JAMA Surgery","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1001\/jamasurg.2015.4516","article-title":"Nomograms to predict recurrence-free and overall survival after curative resection of adrenocortical carcinoma","volume":"151","author":"Kim","year":"2016","unstructured":"Kim YMargonis GAPrescott JDTran TBPostlewait LMMaithel SKWang TSEvans DBHatzaras IShenoy RNomograms to predict recurrence-free and overall survival after curative resection of adrenocortical carcinoma. JAMA Surgery2016151365\u2013373. (https:\/\/doi.org\/10.1001\/jamasurg.2015.4516)10.1001\/jamasurg.2015.4516"},{"key":"bib24","series-title":"Annals of Oncology","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1093\/annonc\/mdv329","article-title":"Prognostic factors in stage III\u2013IV adrenocortical carcinomas (ACC): an European Network for the study of adrenal tumor (ENSAT) study","volume":"26","author":"Libe","year":"2015","unstructured":"Libe RBorget IRonchi CLZaggia BKroiss MKerkhofs TBertherat JVolante MQuinkler MChabre OPrognostic factors in stage III\u2013IV adrenocortical carcinomas (ACC): an European Network for the study of adrenal tumor (ENSAT) study. Annals of Oncology2015262119\u20132125. (https:\/\/doi.org\/10.1093\/annonc\/mdv329)10.1093\/annonc\/mdv329"},{"key":"bib25","series-title":"Endocrine","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s12020-019-02141-2","article-title":"The clinical utility of \u2018GRAS\u2019 parameters in stage I\u2013III adrenocortical carcinomas: long-term data from a high-volume institution","volume":"67","author":"Liang","year":"2020","unstructured":"Liang JLiu ZZhou LTang YZhou CWu KZhang FZhang FWei XLu YThe clinical utility of \u2018GRAS\u2019 parameters in stage I\u2013III adrenocortical carcinomas: long-term data from a high-volume institution. Endocrine202067449\u2013456. (https:\/\/doi.org\/10.1007\/s12020-019-02141-2)10.1007\/s12020-019-02141-2"},{"key":"bib26","series-title":"European Journal of Endocrinology","first-page":"25","article-title":"S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study","volume":"186","author":"Elhassan","year":"2021","unstructured":"Elhassan YSAltieri BBerhane SCosentini DCalabrese AHaissaguerre MKastelan DFragoso MCBVBertherat JAl Ghuzlan AS-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. European Journal of Endocrinology202118625\u201336. (https:\/\/doi.org\/10.1530\/EJE-21-0510)"},{"key":"bib27","series-title":"Journal of Clinical Oncology","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1200\/JCO.2008.18.5678","article-title":"Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival","volume":"27","author":"de Reynies","year":"2009","unstructured":"de Reynies AAssie GRickman DSTissier FGroussin LRene-Corail FDousset BBertagna XClauser EBertherat J. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. Journal of Clinical Oncology2009271108\u20131115. (https:\/\/doi.org\/10.1200\/JCO.2008.18.5678)10.1200\/JCO.2008.18.5678"},{"key":"bib28","series-title":"European Journal of Endocrinology","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1530\/EJE-11-0806","article-title":"Combined expression of BUB1B, DLGAP5, and PINK1 as predictors of poor outcome in adrenocortical tumors: validation in a Brazilian cohort of adult and pediatric patients","volume":"166","author":"Fragoso","year":"2012","unstructured":"Fragoso MCAlmeida MQMazzuco TLMariani BMBrito LPGoncalves TCAlencar GALima Lde Lde OFaria AMBourdeau ICombined expression of BUB1B, DLGAP5, and PINK1 as predictors of poor outcome in adrenocortical tumors: validation in a Brazilian cohort of adult and pediatric patients. European Journal of Endocrinology201216661\u201367. (https:\/\/doi.org\/10.1530\/EJE-11-0806)10.1530\/EJE-11-0806"},{"key":"bib29","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"E161","DOI":"10.1210\/jc.2010-0653","article-title":"High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors","volume":"95","author":"Sbiera","year":"2010","unstructured":"Sbiera SSchmull SAssie GVoelker HUKraus LBeyer MRagazzon BBeuschlein FWillenberg HSHahner SHigh diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. Journal of Clinical Endocrinology and Metabolism201095E161\u2013E171. (https:\/\/doi.org\/10.1210\/jc.2010-0653)10.1210\/jc.2010-0653"},{"key":"bib30","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1210\/jc.2017-00984","article-title":"Assessment of VAV2 expression refines prognostic prediction in adrenocortical carcinoma","volume":"102","author":"Sbiera","year":"2017","unstructured":"Sbiera SSbiera IRuggiero CDoghman-Bouguerra MKorpershoek Ede Krijger RREttaieb HHaak HVolante MPapotti MAssessment of VAV2 expression refines prognostic prediction in adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism20171023491\u20133498. (https:\/\/doi.org\/10.1210\/jc.2017-00984)10.1210\/jc.2017-00984"},{"key":"bib31","series-title":"Human Molecular Genetics","first-page":"2789","article-title":"EZH2 is overexpressed in adrenocortical carcinoma and is associated with disease progression","volume":"25","author":"Drelon","year":"2016","unstructured":"Drelon CBerthon AMathieu MRagazzon BKuick RTabbal HSeptier ARodriguez SBatisse-Lignier MSahut-Barnola IEZH2 is overexpressed in adrenocortical carcinoma and is associated with disease progression. Human Molecular Genetics2016252789\u20132800. (https:\/\/doi.org\/10.1093\/hmg\/ddw136)"},{"key":"bib32","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"E174","DOI":"10.1210\/jc.2012-2993","article-title":"Identification of a CpG island methylator phenotype in adrenocortical carcinomas","volume":"98","author":"Barreau","year":"2013","unstructured":"Barreau OAssie GWilmot-Roussel HRagazzon BBaudry CPerlemoine KRene-Corail FBertagna XDousset BHamzaoui NIdentification of a CpG island methylator phenotype in adrenocortical carcinomas. Journal of Clinical Endocrinology and Metabolism201398E174\u2013E184. (https:\/\/doi.org\/10.1210\/jc.2012-2993)10.1210\/jc.2012-2993"},{"key":"bib33","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"923","article-title":"DNA methylation is an independent prognostic marker of survival in adrenocortical cancer","volume":"102","author":"Jouinot","year":"2017","unstructured":"Jouinot AAssie GLibe RFassnacht MPapathomas TBarreau Ode la Villeon BFaillot SHamzaoui NNeou MDNA methylation is an independent prognostic marker of survival in adrenocortical cancer. Journal of Clinical Endocrinology and Metabolism2017102923\u2013932. (https:\/\/doi.org\/10.1210\/jc.2016-3205)"},{"key":"bib34","series-title":"Clinical Cancer Research","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1158\/1078-0432.CCR-18-2693","article-title":"Targeted Assessment of G0S2 methylation identifies a rapidly recurrent, routinely fatal molecular subtype of adrenocortical carcinoma","volume":"25","author":"Mohan","year":"2019","unstructured":"Mohan DRLerario AMElse TMukherjee BAlmeida MQVinco MRege JMariani BMPZerbini MCNMendonca BBTargeted Assessment of G0S2 methylation identifies a rapidly recurrent, routinely fatal molecular subtype of adrenocortical carcinoma. Clinical Cancer Research2019253276\u20133288. (https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2693)10.1158\/1078-0432.CCR-18-2693"},{"key":"bib35","series-title":"Nature Genetics","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/ng.2953","article-title":"Integrated genomic characterization of adrenocortical carcinoma","volume":"46","author":"Assie","year":"2014","unstructured":"Assie GLetouze EFassnacht MJouinot ALuscap WBarreau OOmeiri HRodriguez SPerlemoine KRene-Corail FIntegrated genomic characterization of adrenocortical carcinoma. Nature Genetics201446607\u2013612. (https:\/\/doi.org\/10.1038\/ng.2953)10.1038\/ng.2953"},{"key":"bib36","series-title":"Cancer Cell","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","article-title":"Comprehensive pan-genomic characterization of adrenocortical carcinoma","volume":"29","author":"Zheng","year":"2016","unstructured":"Zheng SCherniack ADDewal NMoffitt RADanilova LMurray BALerario AMElse TKnijnenburg TACiriello GComprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell201629723\u2013736. (https:\/\/doi.org\/10.1016\/j.ccell.2016.04.002)10.1016\/j.ccell.2016.04.002"},{"key":"bib37","series-title":"JAMA Oncology","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1001\/jamaoncol.2019.1558","article-title":"Value of molecular classification for prognostic assessment of adrenocortical carcinoma","volume":"5","author":"Assie","year":"2019","unstructured":"Assie GJouinot AFassnacht MLibe RGarinet SJacob LHamzaoui NNeou MSakat Jde La Villeon BValue of molecular classification for prognostic assessment of adrenocortical carcinoma. JAMA Oncology201951440\u20131447. (https:\/\/doi.org\/10.1001\/jamaoncol.2019.1558)10.1001\/jamaoncol.2019.1558"},{"key":"bib38","series-title":"Journal for ImmunoTherapy of Cancer","doi-asserted-by":"publisher","first-page":"e000469","DOI":"10.1136\/jitc-2019-000469","article-title":"Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma","volume":"8","author":"Landwehr","year":"2020","unstructured":"Landwehr LSAltieri BSchreiner JSbiera IWeigand IKroiss MFassnacht MSbiera S. Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. Journal for ImmunoTherapy of Cancer20208e000469. (https:\/\/doi.org\/10.1136\/jitc-2019-000469)10.1136\/jitc-2019-000469"},{"key":"bib39","series-title":"Cancers","article-title":"Non-coding RNAs in adrenocortical cancer: from pathogenesis to diagnosis","volume":"12","author":"Decmann","year":"2020","unstructured":"Decmann APerge PTurai PIPatocs AIgaz P. Non-coding RNAs in adrenocortical cancer: from pathogenesis to diagnosis. Cancers202012 461. (https:\/\/doi.org\/10.3390\/cancers12020461)"},{"key":"bib40","series-title":"Endocrine-Related Cancer","doi-asserted-by":"publisher","first-page":"L13","DOI":"10.1530\/ERC-17-0467","article-title":"Detection and monitoring of circulating tumor DNA in adrenocortical carcinoma","volume":"25","author":"Garinet","year":"2018","unstructured":"Garinet SNectoux JNeou MPasmant EJouinot ASibony MOrhant LPipoli da Fonseca JPerlemoine KBricaire LDetection and monitoring of circulating tumor DNA in adrenocortical carcinoma. Endocrine-Related Cancer201825L13\u2013L17. (https:\/\/doi.org\/10.1530\/ERC-17-0467)10.1530\/ERC-17-0467"},{"key":"bib41","series-title":"Cancers","article-title":"Prognostic and monitoring value of circulating tumor cells in adrenocortical carcinoma: a preliminary monocentric study","volume":"12","author":"Cantini","year":"2020","unstructured":"Cantini GCanu LArmignacco RSalvianti FDe Filpo GErcolino TNesi GMaggi MMannelli MPinzani PPrognostic and monitoring value of circulating tumor cells in adrenocortical carcinoma: a preliminary monocentric study. Cancers202012 3176. (https:\/\/doi.org\/10.3390\/cancers12113176)"},{"key":"bib42","series-title":"Journal of Clinical Oncology","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1200\/JCO.2014.55.2836","article-title":"Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies","volume":"32","author":"Berruti","year":"2014","unstructured":"Berruti AAmoroso VGallo FBertaglia VSimoncini EPedersini RFerrari LBottini ABruzzi PSormani MP. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. Journal of Clinical Oncology2014323883\u20133891. (https:\/\/doi.org\/10.1200\/JCO.2014.55.2836)10.1200\/JCO.2014.55.2836"},{"key":"bib43","series-title":"World Journal of Surgery","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1007\/s00268-014-2484-4","article-title":"Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy","volume":"38","author":"Bednarski","year":"2014","unstructured":"Bednarski BKHabra MAPhan AMilton DRWood CVauthey NEvans DBKatz MHNg CSPerrier NDBorderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy. World Journal of Surgery2014381318\u20131327. (https:\/\/doi.org\/10.1007\/s00268-014-2484-4)10.1007\/s00268-014-2484-4"},{"key":"bib44","series-title":"Journal of Surgical Research","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.jss.2021.06.013","article-title":"Factors associated with non-operative management of resectable adrenocortical carcinoma","volume":"267","author":"Tseng","year":"2021","unstructured":"Tseng JDiPeri TChen YBen-Shlomo AShouhed DPhillips EHBurch MJain M. Factors associated with non-operative management of resectable adrenocortical carcinoma. Journal of Surgical Research2021267651\u2013659. (https:\/\/doi.org\/10.1016\/j.jss.2021.06.013)10.1016\/j.jss.2021.06.013"},{"key":"bib45","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1210\/clinem\/dgac046","article-title":"Temporal trends in outcomes in patients with adrenocortical carcinoma: a multidisciplinary referral center experience","volume":"107","author":"Daher","year":"2022","unstructured":"Daher MVarghese JGruschkus SKJimenez CWaguespack SGBedrose SAltameemi LBazerbashi HNaing ASubaiah VTemporal trends in outcomes in patients with adrenocortical carcinoma: a multidisciplinary referral center experience. Journal of Clinical Endocrinology and Metabolism20221071239\u20131246. (https:\/\/doi.org\/10.1210\/clinem\/dgac046)10.1210\/clinem\/dgac046"},{"key":"bib46","series-title":"Annals of Surgical Oncology","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1245\/s10434-015-4900-x","article-title":"Open versus laparoscopic adrenalectomy for adrenocortical carcinoma: a meta-analysis of surgical and oncological outcomes","volume":"23","author":"Autorino","year":"2016","unstructured":"Autorino RBove PDe Sio MMiano RMicali SCindolo LGreco FNicholas JFiori CBianchi GOpen versus laparoscopic adrenalectomy for adrenocortical carcinoma: a meta-analysis of surgical and oncological outcomes. Annals of Surgical Oncology2016231195\u20131202. (https:\/\/doi.org\/10.1245\/s10434-015-4900-x)10.1245\/s10434-015-4900-x"},{"key":"bib47","series-title":"European Urology Focus","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.euf.2015.12.001","article-title":"Surgical management of adrenocortical carcinoma: impact of laparoscopic approach, lymphadenectomy, and surgical volume on outcomes \u2013 a systematic review and meta-analysis of the current literature","volume":"1","author":"Langenhuijsen","year":"2016","unstructured":"Langenhuijsen JBirtle AKlatte TPorpiglia FTimsit MO. Surgical management of adrenocortical carcinoma: impact of laparoscopic approach, lymphadenectomy, and surgical volume on outcomes \u2013 a systematic review and meta-analysis of the current literature. European Urology Focus20161241\u2013250. (https:\/\/doi.org\/10.1016\/j.euf.2015.12.001)10.1016\/j.euf.2015.12.001"},{"key":"bib48","series-title":"Annals of Surgical Oncology","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1245\/s10434-020-08454-1","article-title":"Minimally invasive versus open adrenalectomy in patients with adrenocortical carcinoma: a meta-analysis","volume":"27","author":"Hu","year":"2020","unstructured":"Hu XYang WXShao YXDou WCXiong SCLi X. Minimally invasive versus open adrenalectomy in patients with adrenocortical carcinoma: a meta-analysis. Annals of Surgical Oncology2020273858\u20133869. (https:\/\/doi.org\/10.1245\/s10434-020-08454-1)10.1245\/s10434-020-08454-1"},{"key":"bib49","series-title":"Journal of Endocrinological Investigation","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s40618-015-0422-4","article-title":"Does nephrectomy during radical adrenalectomy for stage II adrenocortical cancer affect patient outcome?","volume":"39","author":"Porpiglia","year":"2016","unstructured":"Porpiglia FFiori CDaffara FCZaggia BArdito AScarpa RMPapotti MBerruti AScagliotti GVTerzolo M. Does nephrectomy during radical adrenalectomy for stage II adrenocortical cancer affect patient outcome?Journal of Endocrinological Investigation201639465\u2013471. (https:\/\/doi.org\/10.1007\/s40618-015-0422-4)10.1007\/s40618-015-0422-4"},{"key":"bib50","series-title":"Cancers","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3390\/cancers14020291","article-title":"Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma \u2013 a systematic review and meta-analysis","volume":"14","author":"Hendricks","year":"2022","unstructured":"Hendricks AMuller SFassnacht MGermer CTWiegering VAWiegering AReibetanz J. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma \u2013 a systematic review and meta-analysis. Cancers202214291\u2013211. (https:\/\/doi.org\/10.3390\/cancers14020291)10.3390\/cancers14020291"},{"key":"bib51","series-title":"Annals of Surgical Oncology","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1245\/s10434-018-6999-z","article-title":"Patterns of lymph node recurrence in adrenocortical carcinoma: possible implications for primary surgical treatment","volume":"26","author":"Reibetanz","year":"2019","unstructured":"Reibetanz JRinn BKunz ASFlemming SRonchi CLKroiss MDeutschbein TPulzer AHahner SKocot APatterns of lymph node recurrence in adrenocortical carcinoma: possible implications for primary surgical treatment. Annals of Surgical Oncology201926531\u2013538. (https:\/\/doi.org\/10.1245\/s10434-018-6999-z)10.1245\/s10434-018-6999-z"},{"key":"bib52","series-title":"American Journal of Surgery","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.amjsurg.2021.10.014","article-title":"Informing therapeutic lymphadenectomy: location of regional metastatic lymph nodes in adrenocortical carcinoma","volume":"223","author":"Sada","year":"2022","unstructured":"Sada AGlasgow AELyden MLDy BMFoster TRHabermann EBBancos IMcKenzie TJ. Informing therapeutic lymphadenectomy: location of regional metastatic lymph nodes in adrenocortical carcinoma. American Journal of Surgery20222231042\u20131045. (https:\/\/doi.org\/10.1016\/j.amjsurg.2021.10.014)10.1016\/j.amjsurg.2021.10.014"},{"key":"bib53","series-title":"Cancers","article-title":"Molecular mechanisms of mitotane action in adrenocortical cancer based on in vitro studies","volume":"13","author":"Lo Iacono","year":"2021","unstructured":"Lo Iacono MPuglisi SPerotti PSaba LPetiti JGiachino CReimondo GTerzolo M. Molecular mechanisms of mitotane action in adrenocortical cancer based on in vitro studies. Cancers202113 5255. (https:\/\/doi.org\/10.3390\/cancers13215255)"},{"key":"bib54","series-title":"Archives of Surgery","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1001\/archsurg.1982.01380330010004","article-title":"Treatment of adrenal carcinomas","volume":"117","author":"Schteingart","year":"1982","unstructured":"Schteingart DEMotazedi ANoonan RAThompson NW. Treatment of adrenal carcinomas. Archives of Surgery19821171142\u20131146. (https:\/\/doi.org\/10.1001\/archsurg.1982.01380330010004)10.1001\/archsurg.1982.01380330010004"},{"issue":"Supplement 7","key":"bib55","series-title":"Annals of Oncology","doi-asserted-by":"publisher","first-page":"vii131","DOI":"10.1093\/annonc\/mds231","article-title":"Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Berruti","year":"2012","unstructured":"Berruti ABaudin EGelderblom HHaak HRPorpiglia FFassnacht MPentheroudakis G & ESMO Guidelines Working Group. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology201223 (Supplement 7) vii131\u2013vii138. (https:\/\/doi.org\/10.1093\/annonc\/mds231)10.1093\/annonc\/mds231"},{"key":"bib56","series-title":"BioMed Research International","article-title":"Benefits of adjuvant mitotane after resection of adrenocortical carcinoma: a systematic review and meta-analysis","volume":"2018","author":"Tang","year":"2018","unstructured":"Tang YLiu ZZou ZLiang JLu YZhu Y. Benefits of adjuvant mitotane after resection of adrenocortical carcinoma: a systematic review and meta-analysis. BioMed Research International20182018 9362108. (https:\/\/doi.org\/10.1155\/2018\/9362108)"},{"key":"bib57","series-title":"Endocrine Abstracts","article-title":"Results of the ADIUVO trial, the first randomized study on post-operative adjuvant mitotane in patients with adrenocortical carcinoma","volume":"73","author":"Terzolo","year":"2021","unstructured":"Terzolo MFassnacht MPerotti PLib\u00e8 RLacroix AKastelan DR. HHArlt WLoli PDecoudier BResults of the ADIUVO trial, the first randomized study on post-operative adjuvant mitotane in patients with adrenocortical carcinoma. Endocrine Abstracts202173 OC11.75. (https:\/\/doi.org\/10.1530\/endoabs.73.OC11.5)"},{"key":"bib58","series-title":"Journal of Clinical Oncology","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1200\/JCO.2009.27.5958","article-title":"Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel","volume":"28","author":"Berruti","year":"2010","unstructured":"Berruti AFassnacht MBaudin EHammer GHaak HLeboulleux SSkogseid BAllolio BTerzolo M. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. Journal of Clinical Oncology201028e401\u2013e402; author reply e403. (https:\/\/doi.org\/10.1200\/JCO.2009.27.5958)10.1200\/JCO.2009.27.5958"},{"key":"bib59","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1210\/jc.2013-2856","article-title":"Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma","volume":"99","author":"Else","year":"2014","unstructured":"Else TWilliams ARSabolch AJolly SMiller BSHammer GD. Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism201499455\u2013461. (https:\/\/doi.org\/10.1210\/jc.2013-2856)10.1210\/jc.2013-2856"},{"key":"bib60","series-title":"Trials","article-title":"Comparison of randomized controlled trials discontinued or revised for poor recruitment and completed trials with the same research question: a matched qualitative study","volume":"20","author":"Briel","year":"2019","unstructured":"Briel MSpeich Bvon Elm EGloy V. Comparison of randomized controlled trials discontinued or revised for poor recruitment and completed trials with the same research question: a matched qualitative study. Trials201920 800. (https:\/\/doi.org\/10.1186\/s13063-019-3957-4)"},{"key":"bib61","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1210\/jc.2019-00029","article-title":"Adjuvant radiation improves recurrence-free survival and overall survival in adrenocortical carcinoma","volume":"104","author":"Gharzai","year":"2019","unstructured":"Gharzai LAGreen MDGriffith KAElse TMayo CSHesseltine ESpratt DEBen-Josef ESabolch AMiller BSAdjuvant radiation improves recurrence-free survival and overall survival in adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism20191043743\u20133750. (https:\/\/doi.org\/10.1210\/jc.2019-00029)10.1210\/jc.2019-00029"},{"key":"bib62","series-title":"Journal of the National Comprehensive Cancer Network","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.6004\/jnccn.2021.7035","article-title":"Benefit of postoperative radiotherapy for patients with nonmetastatic adrenocortical carcinoma: a population-based analysis","volume":"19","author":"Wu","year":"2021","unstructured":"Wu KLiu XLiu ZLu YWang XLi X. Benefit of postoperative radiotherapy for patients with nonmetastatic adrenocortical carcinoma: a population-based analysis. Journal of the National Comprehensive Cancer Network2021191425\u20131432. (https:\/\/doi.org\/10.6004\/jnccn.2021.7035)10.6004\/jnccn.2021.7035"},{"key":"bib63","series-title":"Radiation Oncology","article-title":"Efficacy of adjuvant radiotherapy for treatment of adrenocortical carcinoma: a retrospective study and an updated meta-analysis","volume":"15","author":"Zhu","year":"2020","unstructured":"Zhu JZheng ZShen JLian XMiao ZShen JZhang F. Efficacy of adjuvant radiotherapy for treatment of adrenocortical carcinoma: a retrospective study and an updated meta-analysis. Radiation Oncology202015 118. (https:\/\/doi.org\/10.1186\/s13014-020-01533-3)"},{"key":"bib64","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1210\/jc.2006-1007","article-title":"Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma","volume":"91","author":"Fassnacht","year":"2006","unstructured":"Fassnacht MHahner SPolat BKoschker ACKenn WFlentje MAllolio B. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism2006914501\u20134504. (https:\/\/doi.org\/10.1210\/jc.2006-1007)10.1210\/jc.2006-1007"},{"key":"bib65","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1210\/jc.2012-2367","article-title":"A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma","volume":"98","author":"Habra","year":"2013","unstructured":"Habra MAEjaz SFeng LDas PDeniz FGrubbs EGPhan AWaguespack SGAyala-Ramirez MJimenez CA retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism201398192\u2013197. (https:\/\/doi.org\/10.1210\/jc.2012-2367)10.1210\/jc.2012-2367"},{"key":"bib66","series-title":"International Brazilian Journal of Urology","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1590\/s1677-5538.ibju.2017.0095","article-title":"Adjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: are we offering the best?","volume":"43","author":"Srougi","year":"2017","unstructured":"Srougi Vde Bessa JJrTanno FYFerreira AMHoff AOBezerra JEAlmeida CMAlmeida MQMendonca BBNahas WCAdjuvant radiotherapy for the primary treatment of adrenocortical carcinoma: are we offering the best?International Brazilian Journal of Urology201743841\u2013848. (https:\/\/doi.org\/10.1590\/S1677-5538.IBJU.2017.0095)10.1590\/s1677-5538.ibju.2017.0095"},{"key":"bib67","series-title":"Medical and Pediatric Oncology","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/mpo.10241","article-title":"Adrenocortical carcinoma in children: a role for etoposide and cisplatin adjuvant therapy? Preliminary report","volume":"40","author":"Hovi","year":"2003","unstructured":"Hovi LWikstrom SVettenranta KHeikkila PSaarinen-Pihkala UM. Adrenocortical carcinoma in children: a role for etoposide and cisplatin adjuvant therapy? Preliminary report. Medical and Pediatric Oncology200340324\u2013326. (https:\/\/doi.org\/10.1002\/mpo.10241)10.1002\/mpo.10241"},{"key":"bib68","series-title":"Annals of Oncology","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1023\/A:1008377915129","article-title":"Streptozocin and o,p\u2019DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use","volume":"11","author":"Khan","year":"2000","unstructured":"Khan TSImam HJuhlin CSkogseid BGrondal STibblin SWilander EOberg KEriksson B. Streptozocin and o,p\u2019DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Annals of Oncology2000111281\u20131287. (https:\/\/doi.org\/10.1023\/a:1008377915129)10.1023\/A:1008377915129"},{"key":"bib69","series-title":"British Journal of Cancer","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/s41416-021-01513-8","article-title":"Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study","volume":"125","author":"Kimpel","year":"2021","unstructured":"Kimpel OBedrose SMegerle FBerruti ATerzolo MKroiss MMai KDekkers OMHabra MAFassnacht M. Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study. British Journal of Cancer20211251233\u20131238. (https:\/\/doi.org\/10.1038\/s41416-021-01513-8)10.1038\/s41416-021-01513-8"},{"key":"bib70","series-title":"Journal of Clinical Oncology","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1200\/JCO.20.02871","article-title":"Treatment of pediatric adrenocortical carcinoma with surgery, retroperitoneal lymph node dissection, and chemotherapy: the Children\u2019s Oncology Group ARAR0332 protocol","volume":"39","author":"Rodriguez-Galindo","year":"2021","unstructured":"Rodriguez-Galindo CKrailo MDPinto EMPashankar FWeldon CBHuang LCaran EMHicks JMcCarville MBMalkin DTreatment of pediatric adrenocortical carcinoma with surgery, retroperitoneal lymph node dissection, and chemotherapy: the Children\u2019s Oncology Group ARAR0332 protocol. Journal of Clinical Oncology2021392463\u20132473. (https:\/\/doi.org\/10.1200\/JCO.20.02871)10.1200\/JCO.20.02871"},{"key":"bib71","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1210\/jc.2014-2650","article-title":"Brain metastasis in patients with adrenocortical carcinoma: a clinical series","volume":"100","author":"Burotto","year":"2015","unstructured":"Burotto MTageja NRosenberg AMahalingam SQuezado MVelarde MEdgerly MFojo T. Brain metastasis in patients with adrenocortical carcinoma: a clinical series. Journal of Clinical Endocrinology and Metabolism2015100331\u2013336. (https:\/\/doi.org\/10.1210\/jc.2014-2650)10.1210\/jc.2014-2650"},{"key":"bib72","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1210\/jc.2010-2676","article-title":"Plasma concentrations of o,p\u2019DDD, o,p\u2019DDA, and o,p\u2019DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study","volume":"96","author":"Hermsen","year":"2011","unstructured":"Hermsen IGFassnacht MTerzolo MHouterman Sden Hartigh JLeboulleux SDaffara FBerruti AChadarevian RSchlumberger MPlasma concentrations of o,p\u2019DDD, o,p\u2019DDA, and o,p\u2019DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. Journal of Clinical Endocrinology and Metabolism2011961844\u20131851. (https:\/\/doi.org\/10.1210\/jc.2010-2676)10.1210\/jc.2010-2676"},{"key":"bib73","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1210\/jc.2017-02591","article-title":"Mitotane monotherapy in patients with advanced adrenocortical carcinoma","volume":"103","author":"Megerle","year":"2018","unstructured":"Megerle FHerrmann WSchloetelburg WRonchi CLPulzer AQuinkler MBeuschlein FHahner SKroiss MFassnacht MMitotane monotherapy in patients with advanced adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism20181031686\u20131695. (https:\/\/doi.org\/10.1210\/jc.2017-02591)10.1210\/jc.2017-02591"},{"key":"bib74","series-title":"European Journal of Endocrinology","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1530\/EJE-13-0242","article-title":"Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection","volume":"169","author":"Terzolo","year":"2013","unstructured":"Terzolo MBaudin AEArdito AKroiss MLeboulleux SDaffara FPerotti PFeelders RAdeVries JHZaggia BMitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. European Journal of Endocrinology2013169263\u2013270. (https:\/\/doi.org\/10.1530\/EJE-13-0242)10.1530\/EJE-13-0242"},{"key":"bib75","series-title":"Cancers","article-title":"Mitotane concentrations influence outcome in patients with advanced adrenocortical carcinoma","volume":"12","author":"Puglisi","year":"2020","unstructured":"Puglisi SCalabrese ABasile VCeccato FScaroni CAltieri BDella Casa SLoli PPivonello RDe Martino MCMitotane concentrations influence outcome in patients with advanced adrenocortical carcinoma. Cancers202012 740. (https:\/\/doi.org\/10.3390\/cancers12030740)"},{"key":"bib76","series-title":"Journal of Personalized Medicine","article-title":"What is the optimal duration of adjuvant mitotane therapy in adrenocortical carcinoma? An unanswered question","volume":"11","author":"Basile","year":"2021","unstructured":"Basile VPuglisi SAltieri BCanu LLibe RCeccato FBeuschlein FQuinkler MCalabrese APerotti PWhat is the optimal duration of adjuvant mitotane therapy in adrenocortical carcinoma? An unanswered question. Journal of Personalized Medicine202111 269. (https:\/\/doi.org\/10.3390\/jpm11040269)"},{"key":"bib77","series-title":"Endocrine-Related Cancer","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1677\/ERC-08-0103","article-title":"Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly","volume":"15","author":"Daffara","year":"2008","unstructured":"Daffara FDe Francia SReimondo GZaggia BAroasio EPorpiglia FVolante MTermine ADi Carlo FDogliotti LProspective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocrine-Related Cancer2008151043\u20131053. (https:\/\/doi.org\/10.1677\/ERC-08-0103)10.1677\/ERC-08-0103"},{"key":"bib78","series-title":"Cancers","article-title":"Unwanted hormonal and metabolic effects of postoperative adjuvant mitotane treatment for adrenocortical cancer","volume":"12","author":"Basile","year":"2020","unstructured":"Basile VPuglisi SCalabrese APia APerotti PBerruti AReimondo GTerzolo M. Unwanted hormonal and metabolic effects of postoperative adjuvant mitotane treatment for adrenocortical cancer. Cancers202012 2615. (https:\/\/doi.org\/10.3390\/cancers12092615)"},{"key":"bib79","series-title":"Clinical Endocrinology","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/cen.14345","article-title":"Metabolic and hormonal side effects of mitotane treatment for adrenocortical carcinoma: a retrospective study in 50 Danish patients","volume":"94","author":"Vikner","year":"2021","unstructured":"Vikner MEKrogh JDaugaard GAndreassen M. Metabolic and hormonal side effects of mitotane treatment for adrenocortical carcinoma: a retrospective study in 50 Danish patients. Clinical Endocrinology202194141\u2013149. (https:\/\/doi.org\/10.1111\/cen.14345)10.1111\/cen.14345"},{"key":"bib80","series-title":"Cancers","article-title":"Recovery of adrenal insufficiency is frequent after adjuvant mitotane therapy in patients with adrenocortical carcinoma","volume":"12","author":"Poirier","year":"2020","unstructured":"Poirier JGagnon NTerzolo MPuglisi SGhorayeb NECalabrese ALacroix ABourdeau I. Recovery of adrenal insufficiency is frequent after adjuvant mitotane therapy in patients with adrenocortical carcinoma. Cancers202012 639. (https:\/\/doi.org\/10.3390\/cancers12030639)"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/187\/3\/EJE-22-0260.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/downloadpdf\/journals\/eje\/187\/3\/EJE-22-0260.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/eje.bioscientifica.com\/downloadpdf\/journals\/eje\/187\/3\/EJE-22-0260.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:18:03Z","timestamp":1676391483000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/187\/3\/R27\/6972105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":80,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.1530\/eje-22-0260","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]}}}